DUPIXENT patients achieved significant reduction in nodules vs placebo at Week 24
(secondary endpoint)1,2

PRIME
Proportion (%) of patients with IGA PN-S score of 0 or 1 at Week 24a
  • A nominal difference was observed at Week 4 (9% with DUPIXENT vs 1% with placebo) and at Week 12 (32% with DUPIXENT vs 12% with placebo)2

PRIME2


  • At Week 4, 8% of patients treated with DUPIXENT vs 6% with placebo had nodule clearance. A significantly greater proportion of DUPIXENT patients achieved nodule clearance at Week 12 (26% with DUPIXENT vs 12% with placebo; P=0.0194) and Week 24 (45% with DUPIXENT vs 16% with placebo; P<0.0001)1,2

Definitive conclusions cannot be made for results earlier than at 24 weeks in PRIME and at timepoints other than Weeks 12 and 24 in PRIME2. Data were not multiplicity controlled.

DUPIXENT EFFICACY DEMONSTRATED CONSISTENT TREATMENT EFFECT ACROSS STUDY POPULATION, REGARDLESS OF PATIENTS’ HISTORY OF ATOPY1
  • 57% of patients across PRIME and PRIME2 did not have a history of atopy (defined as having a medical history of atopic dermatitis, allergic rhinitis/rhinoconjunctivitis, asthma, or food allergy)1

See WI-NRS Results

IGA PN-S, Investigator’s Global Assessment PN-Stage; Q2W, once every 2 weeks; SD, standard deviation.


Dosage and Administration

Thinking about prescribing DUPIXENT? Find the information you need to get started.
Explore administration Options